| Aktie | Ticker | Breite | GCS | 2025/Q3 | |||
|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 55.636.803 $ | +33.644.483 $ | +102,6 % | 4 | ||||
| Tourmaline Bio, Inc. | TRML | → 0 | 35.475.081 $ | +23.615.442 $ | +199,1 % | 1 | |
| Korro Bio, Inc. | KRRO | → 0 | Neutral | 17.627.591 $ | +13.030.209 $ | +283,4 % | 1 |
| Jasper Therapeutics, Inc. | JSPR | → 0 | Schwach | 2.210.934 $ | -2.944.816 $ | -57,1 % | 1 |
| Kezar Life Sciences, Inc. | KZR | → 0 | 323.197 $ | -56.352 $ | -14,8 % | 1 | |
| 55.636.803 $ | +33.644.483 $ | +102,6 % | 4 | ||||